Related Experiment Videos

[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]

T Hayashi1, G Tanaka, K Irimura

  • 1Drug Safety Research Laboratory, Taiho Pharmaceutical Co., Ltd, Tokushima, Japan.

Insights

S-1, an antineoplastic drug, caused gastrointestinal and hematological toxicities in animal models. Its toxicity profile is similar to 5-fluorouracil, with CDHP and Oxo not altering the toxicity.

Area of Science:

  • Pharmacology
  • Toxicology
  • Oncology

Context:

  • S-1 is a novel oral fluoropyrimidine formulation containing tegafur (FT), CDHP, and potassium oxonate (Oxo).
  • It aims to improve the pharmacokinetic profile of 5-fluorouracil (5-FU) and reduce gastrointestinal toxicity.
  • This study investigates the single-dose toxicity of S-1 and its components in mice, rats, and dogs.

Purpose:

  • To evaluate the acute toxicity of S-1 and its individual components (CDHP and Oxo).
  • To determine the toxicological effects and lethal dose 50 (LD50) values in different animal species.
  • To compare the toxicity of S-1 with its active metabolite, 5-FU.

Summary:

  • S-1 administration resulted in dose-dependent toxicities including diarrhea, alopecia, weight loss, and hematological/lymphatic impairments in mice and rats.
  • Dogs exhibited vomiting and gastrointestinal distress after S-1 administration.
  • Pathological findings in mice and rats included pulmonary congestion, lymph node discoloration, and bone marrow suppression, while dogs showed primarily lymphatic organ changes.
  • The LD50 of S-1 varied by species, with dogs being more sensitive.
  • The toxicity of S-1 was attributed to hematopoietic and lymphatic impairments, reflecting the known toxicity of 5-FU without significant modification by CDHP or Oxo.

Impact:

  • This study provides crucial safety data for S-1, informing its clinical development and therapeutic use.
  • Understanding the toxicity profile is essential for managing potential side effects in cancer patients.
  • The findings confirm that S-1's toxicity is primarily driven by its 5-FU component, validating its formulation strategy.

Related Concept Videos